Gene: RASSF3
Official Full Name: Ras association domain family member 3provided by HGNC
Gene Summary: The RAS oncogene (MIM 190020) is mutated in nearly one-third of all human cancers. Members of the RAS superfamily are plasma membrane GTP-binding proteins that modulate intracellular signal transduction pathways. A subfamily of RAS effectors, including RASSF3, share a RAS association (RA) domain.[supplied by OMIM, Jul 2003]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO14695 | RASSF3 Knockout cell line (HeLa) | Human | RASSF3 | 1:3~1:6 | Negative | Online Inquiry |
KO14696 | RASSF3 Knockout cell line (HCT 116) | Human | RASSF3 | 1:2~1:4 | Negative | Online Inquiry |
KO14697 | RASSF3 Knockout cell line (HEK293) | Human | RASSF3 | 1:3~1:6 | Negative | Online Inquiry |
KO14698 | RASSF3 Knockout cell line (A549) | Human | RASSF3 | 1:3~1:4 | Negative | Online Inquiry |
RASSF3 Gene Knockout Cell Lines are a powerful tool in molecular biology that facilitate the study of the RASSF3 gene's role in cellular processes such as proliferation, apoptosis, and tumorigenesis. These cell lines are created through advanced gene-editing techniques, such as CRISPR-Cas9, which effectively disrupt the RASSF3 gene's function, allowing researchers to observe the consequences of its loss in a controlled environment.
The primary function of RASSF3 is as a tumor suppressor, and its loss is implicated in various cancers. By utilizing RASSF3 Knockout Cell Lines, scientists can elucidate the molecular pathways influenced by RASSF3, providing insights into the mechanisms driving oncogenesis. The ability to study the phenotypic changes resulting from the knockout enables researchers to explore both the downstream targets and potential compensatory mechanisms involved, empowering discoveries that could lead to novel therapeutic strategies.
From a scientific perspective, these cell lines hold immense potential for applications in cancer research, drug discovery, and personalized medicine. Researchers can employ these models to screen for compounds that restore RASSF3 function or target pathways activated in its absence, paving the way for innovative treatments. Additionally, these knockout models serve as platforms for understanding the specific contributions of RASSF3 in various physiological and pathological contexts.
Compared to other alternatives, RASSF3 Gene Knockout Cell Lines provide a unique advantage by offering a comprehensive, ready-to-use system that saves time and resources in genetic manipulation processes. Furthermore, these cell lines are validated for consistent performance, ensuring reproducibility in experimental outcomes—a critical requirement in research and clinical applications.
For researchers and clinicians aiming to deepen their understanding of cancer biology or explore potential therapeutic avenues, investing in RASSF3 Gene Knockout Cell Lines is invaluable. It aligns with the growing need for precise cellular models that accurately reflect genetic alterations in human diseases. Our company, with its dedication to advancing biological research through high-quality products and expertise in gene editing technologies, is proud to offer these state-of-the-art cell lines that enhance the capabilities of laboratories worldwide. By choosing our RASSF3 Gene Knockout Cell Lines, users are equipped with an essential resource that fosters breakthroughs in scientific understanding and therapeutic development.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.